Insulet, the Acton-based medical device manufacturer and public company, has named a former global chair at multinational bank JPMorgan Chase to its board of directors.
Insulet, the Acton-based medical device manufacturer and public company, has named a former global chair at multinational bank JPMorgan Chase to its board of directors.
Robbie Huffines will assume his new independent director role come Oct. 31 in addition to serving on the board’s audit committee.
He most recently served as JPMorgan Chase’s global chair of investment banking and was a member of the company’s executive committee before retiring in 2024, according to a Thursday press release from Insulet.
"Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world’s leading financial institutions. His strategic insight and deep industry knowledge will be instrumental as Insulet accelerates its growth and continues delivering sustainable value to our shareholders, communities, partners and the patients we serve,” Timothy Scannell, Insulet board chairman, said in a Tuesday press release.
Huffines held several leadership roles at JP Morgan throughout his 32-year tenure with the corporation.
From 1992 until 2002 he worked in the company’s mergers and acquisitions group, concentrating on the healthcare industry. He then moved on to be co-head of the firm’s global healthcare investment banking group for eight years before assuming his role as vice chairman of investment banking for nine.
Huffines and his wife Lisa Huffines founded The Forest Group, a South Carolina-based nonprofit aimed at developing community-driven mental health solutions for the youth of Charleston, according to the organization's website.
The Forest Group obtained tax-exempt status from the Internal Revenue Service in 2024, according to nonprofit financial tracker GuideStar.
Huffines served on the board of Illinois-based Walgreens Boots Alliance, the parent company of Walgreens, before its acquisition by New York-based Sycamore Partners in August.
He is a board member of Nextech Invest, a venture capital firm out of Switzerland, Eikon Therapeutics, a California-based biopharmaceutical company, and The Hastings Center, a New York-based bioethics research institute.
He graduated with his MBA from University of Virginia’s Darden School of Business and earned his bachelor’s degree from University of North Carolina at Chapel Hill.
"I’m excited to join Insulet’s board at such a pivotal time in the company’s journey," Huffines said in the release. "Insulet’s commitment to innovation and improving the lives of people with diabetes is deeply inspiring. I look forward to working alongside the Board and leadership team to help advance the company’s mission and drive long-term value for all stakeholders."
On Thursday morning, Insulet’s stock was trading at $324.76 per share on the Nasdaq, a 1.4% drop from its share price at market open. Year to date, the company’s stock price has risen 26.4%.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
